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Abstract
Purpose To investigate the effects of chronic beta-alanine (BA) supplementation on muscle taurine content, blood clinical 
markers and sensory side-effects.
Methods Twenty-five healthy male participants (age 27 ± 4 years, height 1.75 ± 0.09 m, body mass 78.9 ± 11.7 kg) were sup-
plemented with 6.4 g day−1 of sustained-release BA (N = 16; CarnoSyn™, NAI, USA) or placebo (PL; N = 9; maltodextrin) 
for 24 weeks. Resting muscle biopsies of the m. vastus lateralis were taken at 0, 12 and 24 weeks and analysed for taurine 
content (BA, N = 12; PL, N = 6) using high-performance liquid chromatography. Resting venous blood samples were taken 
every 4 weeks and analysed for markers of renal, hepatic and muscle function (BA, N = 15; PL, N = 8; aspartate transaminase; 
alanine aminotransferase; alkaline phosphatase; lactate dehydrogenase; albumin; globulin; creatinine; estimated glomerular 
filtration rate and creatine kinase).
Results There was a significant main effect of group (p = 0.04) on muscle taurine, with overall lower values in PL, although 
there was no main effect of time or interaction effect (both p > 0.05) and no differences between specific timepoints (week 
0, BA: 33.67 ± 8.18 mmol kg−1 dm, PL: 27.75 ± 4.86 mmol kg−1 dm; week 12, BA: 35.93 ± 8.79 mmol kg−1 dm, PL: 
27.67 ± 4.75 mmol kg−1 dm; week 24, BA: 35.42 ± 6.16 mmol kg−1 dm, PL: 31.99 ± 5.60 mmol kg−1 dm). There was no 
effect of treatment, time or any interaction effects on any blood marker (all p > 0.05) and no self-reported side-effects in 
these participants throughout the study.
Conclusions The current study showed that 24 weeks of BA supplementation at 6.4 g day−1 did not significantly affect muscle 
taurine content, clinical markers of renal, hepatic and muscle function, nor did it result in chronic sensory side-effects, in 
healthy individuals. Since athletes are likely to engage in chronic supplementation, these data provide important evidence 
to suggest that supplementation with BA at these doses for up to 24 weeks is safe for healthy individuals.
Keywords Chronic beta-alanine supplementation · Muscle taurine · Clinical markers · Safety · Side-effects
Introduction
Beta-alanine (BA) is an effective nutritional supplement to 
improve exercise capacity and performance via increased 
muscle carnosine (β-alanyl-l-histidine) content [1]. It has 
been shown that supplementation with BA over a period of 
4–24 weeks can increase skeletal muscle carnosine content 
[1–3], and the ergogenic potential of increased muscle car-
nosine has been demonstrated in several exercise models [4, 
5]. Despite considerable solid evidence to support the use 
of BA to improve performance, information is lacking on 
the safety of long-term supplementation. Considering the 
increasing popularity of BA [6], it is vital to determine if 
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supplementation at recommended doses could lead to any 
adverse outcomes.
One concern relating to chronic BA supplementation 
is the possible depletion of intramuscular taurine con-
tent which may negatively impact muscle function and 
subsequently exercise and health. Taurine is a β-sulfonic 
amino acid present in human tissues and performs a vari-
ety of important biological roles in skeletal muscle, such 
as osmoregulation, cation homeostasis, enzyme activity, 
receptor regulation, cell development and signalling, and 
cytoprotective activity [7, 8]. Trans-sarcolemmal transport 
of BA into muscle is predominantly mediated by TauT [9], 
a sodium- and chloride-dependent transporter [10] also 
responsible for the transport of taurine into muscle, meaning 
BA may act as an antagonist of taurine uptake, particularly 
if taken in concentrations exceeding habitual dietary levels 
(i.e., supplementation). Indeed, BA is routinely employed to 
induce taurine depression in rats [9, 11], albeit at far higher 
relative doses than those employed in human studies, leading 
to severe health implications and early death [12]. A moder-
ate negative association between intramuscular taurine and 
carnosine with BA supplementation has been reported in 
humans [13]. Since we have recently shown that prolonged 
supplementation with BA results in a chronic downregula-
tion of TauT [3], one could speculate that long-term sup-
plementation may deplete muscle taurine content. Since this 
may have drastic consequences for skeletal muscle function 
[12], it is important to determine whether prolonged sup-
plementation with BA at commonly employed doses results 
in any changes to the intramuscular taurine content.
The long-term effects of high-doses of BA on health-
related markers remain poorly explored. Since the majority 
of BA is metabolised in the liver and kidney following sup-
plementation [14], it is of importance to determine if chronic 
supplementation could overburden these organs. Previous 
research has shown no adverse effect on 12-lead electrocar-
diogram, clinical chemistry or haematological safety data 
after 4 weeks of BA supplementation at 3.2 g day−1 [2]. 
This was confirmed by Stellingwerff et al. [15] after 4 weeks 
with 3.2 g day−1 followed by 4 weeks of 1.6 g day−1, and 
a total 8 weeks of 1.6 g day−1. Twelve weeks of supple-
mentation at 3.2 g day−1 in elderly (60–80 years old) par-
ticipants also showed no adverse effects on clinical health 
markers [16]. However, these studies used relatively low 
doses (≤ 3.2 g day−1) and short supplementation periods 
(≤ 12 weeks). The effects of longer term (i.e., > 12 weeks) 
supplementation with BA at recommended doses (i.e., 
> 3.2 g day−1; [17]) on health parameters related to hepatic, 
renal and muscle function are unknown. Considering a 
chronic and high-dose approach to supplementation is likely 
to be taken by certain athletic populations [6], it is important 
to determine if higher intake may be harmful or inhibitory 
to health.
The only currently known side-effect of BA supplementa-
tion is paraesthesia, described as an uncomfortable sensa-
tion on the surface of the skin that occurs within 10–20 min 
following ingestion [2]. A number of possible mechanisms 
exist for paraesthesia, with the most likely being related to 
the Mas-related gene family of G-protein-coupled receptors, 
which are triggered by interactions with ligands including 
BA [18]. Symptoms typically arise from a high dose of BA, 
although they are substantially decreased when BA is taken 
in the form of slow-release tablets [19]. As paraesthesia does 
not necessarily impose any health risk per se, this symptom 
could be considered a side-effect instead of an adverse effect. 
However, given the relatively common reports of paraes-
thesia in short-term studies, and how little is known about 
the physiological consequences thereof, it is important to 
monitor this over a prolonged follow-up period to determine 
whether increased incidence or symptom aggravation occurs 
as a function of time.
The aim of this study was to examine the effect of 
24 weeks of 6.4 g day−1 BA supplementation on muscle tau-
rine content, blood parameters of renal, hepatic and muscle 
function, and self-reported side-effects. Our a priori hypoth-
eses were that BA would not significantly affect blood health 
parameters or chronic side-effects, but that muscle taurine 
content would be reduced over the supplementation period, 
although remaining within the physiological range.
Methods
Participants
Twenty-five physically active males [age: 27 ± 4 years, 
height: 1.75 ± 0.09 m, body mass (BM): 78.9 ± 11.7 kg] 
completed the study following two drop-outs who cited 
personal reasons for their withdrawal. The participants 
were randomly allocated to either a BA or placebo (PL) 
group, matched for maximum cycling power output attained 
during an incremental cycling test to exhaustion [20]; these 
exercise data are not presented here [3]. Participants were 
fully informed of any risks and discomforts associated with 
the study before completing a health screen and providing 
informed consent. Individuals were required not to have 
taken any supplement in the 3 months prior to the study and 
had not taken BA for at least 6 months prior to the study. 
Participants maintained similar levels of physical activity 
and dietary intake for the duration of the study and compli-
ance with this was confirmed and is presented elsewhere [3]. 
The study was approved by the institution’s Ethical Advisory 
Committee and has been performed in accordance with the 
ethical standards in the 1964 Declaration of Helsinki and its 
later amendments. This was part of a larger thematic project 
with two distinct aims, namely, the effect of 24 weeks BA 
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supplementation on, (1) muscle carnosine content, carnos-
ine-related gene expression and exercise performance, and 
(2) muscle taurine content, clinical markers and sensory 
side-effects. The remaining data are presented elsewhere [3].
Experimental design
Participants attended the laboratory on nine separate occa-
sions. The first two visits were for the determination of each 
participant’s cycling maximal power output and familiari-
sation of the main exercise protocol (data not presented). 
The remaining visits were for the completion of the main 
trials. One main trial was completed before supplementa-
tion, followed by one main trial every 4 weeks for 24 weeks 
of a double-blind supplementation programme, during 
which participants were randomly allocated in a 2:1 ratio 
to ingest BA or PL. The unbalanced design was adopted a 
priori to minimize the number of individuals being biopsied. 
The dosing regimen consisted of the consumption of two 
800 mg tablets of BA (CarnoSyn™, NAI, USA) or placebo 
(PL; maltodextrin, NAI, USA) four times per day at 3–4 h 
intervals to avoid paraesthesia [2], totalling 6.4 g day−1. 
Participants completed a log to verify compliance (BA: 
95 ± 6%; PL: 93 ± 6%); one individual who supplemented 
with BA did not adhere to the supplementation protocol and 
was removed from any analyses. Blinding occurred via an 
outside researcher who allocated individuals into either BA 
or PL. Identical white bottles containing only the partici-
pants’ names were provided to the researchers. All partici-
pants were informed about the associated side-effects with 
BA supplementation (i.e., paraesthesia) and were asked to 
report any perceived symptoms at every laboratory visit 
throughout supplementation. Participants were requested to 
identify which supplement they believed they had ingested 
following their final visit (week 24).
Experimental procedures
Participants abstained from alcohol and caffeine and strenu-
ous exercise in the 24 h period prior to the initial trial and 
arrived at the laboratory a minimum of 4 h following their 
last consumption of food. A cannula was first inserted into 
the antecubital vein to allow for venous blood collection, 
performed with the individual in a supine position. The par-
ticipants then underwent a muscle biopsy of the m. vastus 
lateralis.
Muscle biopsies
Muscle biopsies were taken at rest using a 5 mm biopsy 
Allandale needle (Northern Hospital Supplies, Edinburgh, 
UK) adapted from Bergstrom [21], described in detail else-
where [22]. Briefly, following local anaesthesia (lidocaine 
1%) of the skin, the individual’s dominant leg was prepared 
for skeletal muscle biopsy sampling via an incision along 
the m. vastus lateralis. Approximately 50 mg of muscle 
was taken and snap-frozen in liquid nitrogen and stored at 
− 80 °C until subsequent analysis. Biopsies followed the 
same standardised pattern across individuals. The location 
of the initial biopsy was at a point 25 cm proximal from the 
tuberositas tibiae and 5 cm lateral from the midline of the 
femoral course; the second incision was performed adja-
cent (~ 1 cm) to the first. The following incisions were made 
superior to the previous ones; since this was part of a larger 
project, all participants underwent a total of seven muscle 
biopsies every 4 weeks which resulted in three pairs of par-
allel incisions and one single incision at the most superior 
point. Samples taken at weeks 0, 12 and 24 were analysed 
for muscle taurine content.
Chromatographic determination of taurine in whole 
muscle
Muscle samples were lyophilised and powdered before 
a ~ 6 mg amount was combined with 300 µl of G22 (solu-
tion of 0.5 M perchloric acid  [HClO4] and 1 mM EDTA) 
and homogenized using vortex for 15 min. Samples were 
then centrifuged for 3  min at 3000 rev·min−1 at 4  °C. 
The resultant supernatant was weighed and used to cal-
culate the extract volume accordingly (volume of super-
natant divided by 1.025), which was subsequently multi-
plied by 2.5 to obtain the volume of G23 (2.1 M solution 
of potassium bicarbonate;  KHCO3) to be added. The G23 
was added to the solution while vortexing to allow a salt 
precipitate to form according to the following reaction: 
 KHCO3 + HClO4 → KClO4 + CO2 + H2O. The resultant  CO2 
was dissipated by vortexing before the sample was centri-
fuged for 3 min at 3000 rev·min−1 at 4 °C. The resultant 
supernatant was extracted using a centrifugal filter (0.2 µm), 
checked to ensure a pH close to 7 and then stored at − 80 °C 
until HPLC analysis.
Taurine content in whole muscle was measured using 
HPLC coupled to fluorescence detection, according to an 
adapted method [23, 24]. The column used for chroma-
tographic separation was an ODS HYPERSIL column 
(4.6 × 150 mm, 5 µm) from Thermo Scientific (Waltham, 
Massachusetts, USA) attached to a universal uniguard 
holder with drop-in guards (4 × 10 mm, 5 µm). Prior to 
HPLC injection, a derivatisation agent was added to each 
sample. The derivatisation agent, composed of 0.5  M 
borate buffer (pH 10.4), ø-phthalaldehyde (40 mg/1 ml 
100% ethanol) and 3-propionic acid (250:20:1 v/v/v), was 
prepared 24 h prior to use and stored in the dark at ~ 2 °C. 
Norleucine (0.25 mM) was used as an internal control 
for any variation in expression following derivatization. 
Immediately prior to injection, 12 µl of derivatization 
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reagent was combined with 6 µl of norleucine and 6 µl of 
sample extract. Due to insufficient sample, taurine analysis 
was only performed for 12 individuals in BA and 6 in PL.
The column was equilibrated for 5 min under initial 
conditions prior to each injection. The method used three 
mobile phases: mobile phase A: 20 mM phosphate buffer 
and tetrahydrofuran (995:5, v/v). Mobile phase B: 20 mM 
phosphate buffer, methanol and acetonitrile (500:350:150, 
v/v). Mobile phase C: 100% methanol. The phosphate 
buffer used in mobile phases A and B were made up of 
5.68 g sodium phosphate dibasic  (Na2HPO4) and 4.79 g 
monosodium phosphate  (NaH2PO4) in ultrapure water 
made up to a volume of 2 l and adjusted to pH 6.8. Gradi-
ent elution composition was as follows: 0 min 100% sol-
vent A; 1.5 min 100% solvent A; 17.5 min 50% A 50% 
B; 19.5 min 100% B; 20 min 100%B; 22 min 50% B 50% 
C; 24 min 100% C; 26 min 50% B 50% C; 30 min 100% 
B. The flow-rate was 1.6 ml·min−1 for 17.5 min and 0.8 
ml·min−1 for 12.5 min; total analysis time was 30 min 
per sample. Taurine concentration was determined using 
fluorescence at excitation and emission wavelengths of 
340 nm and 450 nm. All chromatography was carried out 
at room temperature. Quantification of concentrations 
was performed using peak areas, calculated by computer 
software coupled to the Chromatographer. Peak area val-
ues for the standard curve were plotted and a regression 
equation obtained from which interpolations were used to 
calculate content. The intra assay coefficient of variation 
(CV) of taurine between duplicate injections of all analy-
ses (N = 54) was 5.0 ± 4.2%.
Blood collection and analyses
Two resting venous blood samples of 4 and 5 ml were col-
lected into EDTA and SST vacutainer tubes (BD, USA) for 
analyses of aspartate transaminase, alanine aminotrans-
ferase, alkaline phosphatase, lactate dehydrogenase, 
albumin, globulin, creatinine, creatine kinase and uric 
acid. Estimated glomerular filtration rate was determined 
using blood creatinine values using the Cockcroft–Gault 
formula:
All blood samples were taken with the individuals in a 
supine position. All samples were stored at room tempera-
ture and submitted to a central laboratory (Clinical Hospi-
tal of São Paulo) for analysis within 4 h of collection. The 
hospital specialises in the clinical analyses performed with 
annual CVs for the blood analytes measured between 1.75 
and 3.59%. The reference values provided by the hospital’s 
central laboratory were used to classify whether each indi-
vidual analyte was within the normal range of the laboratory.
GFR = [(140 − Age) × BM]∕72 × Creatinine.
Statistical analyses
All data were analysed using the SAS statistical package, 
(SAS 9.2, SAS Institute Inc., USA) and are presented as 
mean ± 1SD and 95% confidence interval (CI), unless oth-
erwise stated. Data were analysed for normality using the 
Shapiro–Wilk tests and for homogeneity and variance/sphe-
ricity using the Mauchly test (all p > 0.05). Muscle taurine 
was analysed using mixed model analysis with individuals 
assumed as a random factor and group (2 levels; BA and PL) 
and time (3 levels; week 0, 12 and 24) assumed as fixed fac-
tors. Tukey–Kramer adjustments were performed whenever 
a significant F value was obtained, and the significance level 
was set a priori at p ≤ 0.05. Blood parameters were analysed 
using mixed model analysis with individuals assumed as a 
random factor and group (2 levels; BA and PL) and time (7 
levels; week 0 to week 24) assumed as fixed factors. Gener-
alized estimating equations (GEE) were performed to com-
pare groups regarding the proportion of participants outside 
of the normal range at each week. Finally, the Fischer exact 
test was used to compare the number of participants who 
correctly guessed their allocation in each group.
Results
Muscle taurine content
There were no significant differences in the pre-sup-
plementation taurine content between BA (week 0: 
33.67 ± 8.18 mmol kg−1 dm, 95% CI 29.04, 38.30) and 
PL (week 0: 27.75 ± 4.86 mmol kg−1 dm, 95% CI 25.36, 
30.13; p = 0.21). There was a significant main effect of 
group (p = 0.04), with overall lower values in PL, although 
there was no main effect of time or interaction effect (both 
p > 0.05; Fig. 1) meaning there were no differences between 
groups at week 12 (BA: 35.93 ± 8.79 mmol kg−1 dm; PL: 
27.67 ± 4.75 mmol kg−1 dm) or week 24 (BA: 35.42 ± 6.16 
mmol kg−1 dm; PL: 31.99 ± 5.60 mmol kg−1 dm).
Blood parameters
One individual from PL showed abnormally high values (> 2 
SDs from the mean) for several health markers at week 0 
(aspartate transaminase, alanine aminotransferase, alkaline 
phosphatase) as indicated by the clinical analysis. Data were 
analysed with and without this individual and showed no dif-
ferences in the main outcomes. Therefore, since this study 
focused on a healthy population, data for this individual 
were removed from any subsequent analysis in their entirety.
At week 0, there was no difference between BA and 
PL for any marker of health (all p > 0.05). There were no 
group, time or interaction effects for any health parameter 
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(all p > 0.05; Table 1). Blood markers at every time point 
were within the normal range for both BA and PL (Table 1). 
Further analysis revealed a few individuals that showed val-
ues outside the normal profile range of the measurements at 
various time points (Table 2), although GEE analysis did not 
show any significant differences between groups regarding 
the proportion of individuals with values outside the normal 
profile range of the measurements for any of the blood mark-
ers measured (all p > 0.05).
Self‑reported side‑effects and supplement 
identification
No self-reported side-effects occurred throughout the sup-
plementation period in either BA or PL. Eight individuals 
in BA correctly identified the supplement they had ingested, 
while the remaining seven incorrectly believed they had 
ingested placebo. In PL, four individuals believed they had 
been allocated to the BA group, and the other four correctly 
identified themselves to be in PL. There were no significant 
differences between groups regarding supplement identifica-
tion (Fisher’s exact test: p = 0.51).
Discussion
These novel data showed that 24 weeks of BA supplementa-
tion at 6.4 g day−1 did not (1) result in any changes in muscle 
taurine content throughout the supplementation period, (2) 
affect clinical markers of renal, hepatic and muscle function, 
and, (3) result in any self-reported side-effects. Since a high 
proportion of athletes have been shown to ingest BA [6], 
many of which are likely to adopt long-term and high-dose 
supplementation strategies, these data provide important 
information to suggest that this type of approach to sup-
plementation will not negatively impact upon the health 
parameters measured here.
Our data showed that chronic BA supplementation did 
not significantly affect the muscle taurine content, extending 
previous work following shorter supplementation periods 
at lower doses [1, 2]. Since BA has been shown to decrease 
muscle taurine in rats [11, 25], leading to the impairment of 
skeletal muscle function [12, 26, 27] and even early death 
[12], it was important to determine whether prolonged sup-
plementation could similarly lead to a decreased muscle 
taurine content in humans, and if so, the subsequent effects 
thereof. We showed no changes in taurine content, despite 
chronic supplementation resulting in a downregulation 
of taurine transporter expression in these individuals [3]. 
Muscle taurine was similarly unaffected following down-
regulation of the TauT transporter with 7 days of taurine 
supplementation [28], suggesting that the skeletal muscle 
taurine pool is tightly regulated and that homeostasis can 
be maintained even when the expression of the TauT gene is 
affected. Indeed, muscle taurine content appears unaffected 
by exercise [28] and aging [29], while the current data sug-
gest that it is unchanged with chronic BA supplementation 
in humans at high doses used by athletes [1, 2, 30]. The 
mechanisms through which muscle taurine content is kept 
constant in humans should be further investigated.
There was substantial interindividual variation in the ini-
tial taurine content (22–54 mmol kg−1), as has been shown 
with muscle carnosine [3], although whole muscle taurine 
was not correlated to muscle carnosine in the present study 
(data not shown). Contrary to changes in muscle carnosine 
with BA supplementation [1–3], muscle taurine was unaf-
fected, although some isolated individuals, irrespective 
of supplementation, showed some changes in muscle tau-
rine content. We could speculate that slight differences in 
the location of the pre-to-post biopsy sites could partially 
explain this individual variability, since type I fibres have 
been shown to have up to four times the taurine content 
shown in type II fibres [31]. Despite a considerable range 
in the absolute content, muscle taurine appears unaffected 
by BA at the current and most commonly employed dose of 
6.4 g day−1.
Twenty-four weeks of BA supplementation did not sig-
nificantly alter clinical markers of health, as measured by 
several markers of renal, hepatic and muscle function. This 
builds upon previous studies showing that lower doses of 
BA for between 4 and 12 weeks, up to a total of 268.8 g of 
BA, do not affect blood clinical chemistry [2, 15, 16]; in 
the current study, participants ingested a total of 1075.2 g 
of BA over 24 weeks. Although a few isolated individual 
blood marker values were changed throughout the follow-up 
Fig. 1  Muscle taurine in the beta-alanine (BA; N = 12) and placebo 
(PL; N = 6) groups. *p = 0.04 Main effect of group. Data are mean ± 1 
SD
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period, this is unlikely due to BA supplementation, since 
these were similar in both the BA and PL groups and GEE 
analysis revealed no significant difference in the number 
of points outside the normal range between groups for any 
marker. Furthermore, most of the individuals who showed 
markers outside of the normal range at timepoints through-
out the supplementation period were those who had slightly 
elevated levels at week 0 (i.e., prior to the supplementation 
period). It appears that BA supplementation at 6.4 g day−1 
could result in minor, non-clinically meaningful changes in 
some of these markers depending on individual differences 
(e.g., baseline health markers, dietary intake). These data 
show that prolonged supplementation with BA at the dose 
given for 24 weeks did not have negative health implications 
for healthy volunteers, as measured by these indices of renal, 
hepatic and muscle function.
There were no self-reported side-effects of paraesthesia 
in the present study, suggesting that the sustained-release 
tablets were successful in avoiding a quick and large release 
of BA into the circulation, which causes this uncomfort-
able sensation. Symptoms of paraesthesia have previously 
been shown to be dose-dependent; ingestion of a 40 mg kg−1 
BM dose of BA in powder form resulted in substantially 
uncomfortable symptoms of paraesthesia [2], while a lower 
20 mg kg−1 BM, which would equate to an equivalent sin-
gle dose used in the current study in an 80 kg individual, 
and 10 mg·kg−1 BM similarly resulted in symptoms but 
less intense. Decombaz et al. [19] have previously shown 
that administration of 1.6 g of BA in slow-release tablets 
resulted in significantly lower sensory side-effects than the 
same BA dose administered as a solution, and that the symp-
toms associated with the slow-release tablets could not be 
differentiated from those associated with placebo ingestion. 
Several individuals in their study reported minor incidence 
of symptoms, which is contrary to the participants in the 
current study. This may be due to the specific aims of the 
two studies; Decombaz et al. [19] explicitly investigated the 
occurrence of side-effects and participants were required to 
respond to a questionnaire at a number of time points fol-
lowing acute ingestion of BA. Had the participants in our 
study been required to respond to a questionnaire, it is pos-
sible we may have shown small incidences of paraesthesia. 
Nonetheless, the results of our study suggest that ingesting 
1.6 g of sustained-release BA interspersed by a minimum of 
3 h throughout the day is unlikely to result in any perceiv-
able side-effects.
We did not determine muscle l-histidine in the current 
study, which may have provided insight into the chronic 
effects of BA on this intramuscular amino acid, which is 
essential for carnosine synthesis. It has been suggested that 
a reduction in muscle histidine could affect muscle protein 
synthesis [30] or histamine kinetics [15], which may impact 
muscle function and impair exercise. Twenty-three days of 
BA supplementation at 6 g day−1 has been shown to reduce 
Table 2  Number of individuals 
in each group at every time 
point that fell above or below 
the normal range
Marker Group Week 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24
Aspartate transaminase BA
PL
0/15
0/8
0/15
0/8
1/15
1/8
0/15
0/8
1/15
0/8
2/15
0/8
0/15
0/8
Alanine aminotransferase BA
PL
2/15
1/8
3/15
1/8
2/15
1/8
1/15
1/8
2/15
0/8
3/15
0/8
2/15
0/8
Alkaline phosphatase BA
PL
1/15
0/8
1/15
0/8
1/15
0/8
0/15
0/8
1/15
0/8
1/15
1/8
1/15
1/8
Lactate dehydrogenase BA
PL
2/15
1/8
2/15
1/8
1/15
1/8
3/15
1/8
2/15
2/8
4/15
2/8
2/15
1/8
Total protein BA
PL
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
Albumin BA
PL
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
Globulin BA
PL
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
Uric acid BA
PL
0/15
1/8
1/15
2/8
1/15
1/8
2/15
1/8
1/15
0/8
1/15
1/8
1/15
0/8
Creatinine BA
PL
3/15
1/8
2/15
0/8
1/15
1/8
2/15
0/8
1/15
0/8
3/15
2/8
1/15
0/8
Estimated GFR BA
PL
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
0/15
0/8
Creatine kinase BA
PL
3/15
1/8
2/15
2/8
1/15
2/8
4/15
3/8
3/15
2/8
4/15
3/8
5/15
1/8
Platelets BA
PL
1/15
0/8
1/15
0/8
1/15
0/8
0/15
0/8
1/15
0/8
1/15
0/8
1/15
0/8
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the intramuscular l-histidine content [30], and this reduced 
muscle histidine availability has been suggested to impair 
the efficiency of carnosine loading with BA as supple-
mentation is extended over time. However, these data have 
not been replicated, with no change in histidine following 
BA supplementation at 12 g day−1 for 2 weeks [32] and 
6 g day−1 for 4 weeks [32–34].
The current study showed that 24 weeks of BA supple-
mentation at 6.4 g day−1 did not negatively impact muscle 
taurine content, clinical markers of renal, hepatic or muscle 
function, nor did it result in any chronic sensory side-effects. 
Since athletes are likely to engage in prolonged periods of 
supplementation, these data provide important evidence to 
suggest that, if they are healthy individuals, they can safely 
supplement with BA at these high doses for up to 24 weeks. 
Further work should elucidate the tolerable upper intake 
level that poses no risk for adverse effects to the general 
population.
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